Roles of PI3K/AKT/PTEN Pathway as a Target for Pharmaceutical Therapy
Satoru Matsuda*, $, Atsuko Nakanishi, Yoko Wada , Yasuko Kitagishi$
Identifiers and Pagination:Year: 2013
First Page: 23
Last Page: 29
Publisher ID: TOMCJ-7-23
Article History:Received Date: 2/9/2013
Revision Received Date: 23/9/2013
Acceptance Date: 5/10/2013
Electronic publication date: 31/10/2013
Collection year: 2013
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Multiple enzymes participate in the phosphorylation of a group of phosphoinositide lipids. Because of their important role in signal transduction, the dysregulated metabolism of phosphoinositides represents a key step in many disease settings. Loss of their function has been demonstrated to occur as an early event a wide variety of carcinogenesis and has therefore been suggested as a biomarker for the premalignant disease. In addition, genetic alterations at multiple nodes in the pathway have been implicated in several other diseases. Accordingly, given this pervasive involvement in many diseases, the development of molecules that modulates this pathway has been initiated in studies. They have been the focus of extensive research and drug discovery activities. A better understanding of the molecular connections could uncover new targets for drug development.